| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4861 | LY-2857785 | 1619903-54-6 | LY2857785 is a novel, potent, selective, type I reversible and competitive ATP kinase inhibitor againstCDK9(IC5011 nM) and other transcription kinasesCDK8(IC5016 nM), andCDK7(IC50246 nM). |
|
V4858 | LY-2922470 | 1423018-12-5 | LY2922470 is a novel, potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist withEC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. |
|
V4884 | LY-3295668 | 1919888-06-4 | LY3295668 (LY-3295668; AK-01; Erbumine;AK01) is a novel, potent, orally bioavailable and highly selectiveAurora-A kinaseinhibitor with potential anticancer activity. |
|
V4865 | LY-450108 | 376594-67-1 | LY450108 is a potent AMPA receptor enhancer. |
|
V4885 | LY223982 | 117423-74-2 | LY 223982 is a novel, potent and specific BLT1 (leukotriene B4) receptor antagonist with anIC50of 13.2 nM against [3H]LTB4 binding to LTB4 receptor. |
|
V4857 | LY2812223 | 1311385-20-2 | LY2812223 is a novel, highly potent, functionally selectivemGlu2receptoragonist with mGlu2binding affinity (Ki) of 144 nM and 156 nM for mGlu2and mGlu3, respectively. |
|
V4859 | LY2881835 | 1292290-38-0 | LY2881835 is a novel, potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist. |
|
V4860 | LY2922083 | 1309435-78-6 | LY2922083 is a novel, potent, selective and orally bioavailable GPR40 (G protein-coupled receptor 40) agonist. |
|
V4849 | LY2979165 | 1311385-32-6 | LY2979165, a novel and potent mGlu2 agonist being developed as an anti-depressant drug candidate, has potential usefulness in the treatment of bipolar disorder. |
|
V4843 | LY3000328 | 1373215-15-6 | LY3000328 is a novel, potent and selective Cathepsin S (Cat S) inhibitor withIC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively. |
|
V4882 | LY3020371 HCl | 1377615-44-5 | LY3020371 HCl is a novel, potent, selective mGlu2/3 (metabotropic glutamate 2/3) receptor antagonist withKiof 5.3 and 2.5 nM, potently blocks cAMP formation withIC50of 16.2 nM. |
|
V4855 | Ly93 | 1883528-69-5 | Ly93 (SMS2-IN-Ly93) is a novel, potent, selective and oral bioavailablesphingomyelin synthase 2 (SMS2)inhibitor with anIC50of 91 nM, showing more than 1400-fold selectivity over sms1 |
|
V4770 | MB-07811 (VK-2809) | 852948-13-1 | MB-07811 (also known as prodrug of MB-07344, and VK-2809), a liver-targetedthyroid hormone receptor-β(TRB) agonist, is a novel, potent and orally bioavailable HepDirect prodrug of MB07344. |
|
V4652 | Mc-MMAF | 863971-19-1 | Mc-MMAF (Mafodotin; SGD-1269 or Maleimidocaproyl monomethylauristatin F) is a protective group-conjugated MMAFhaving a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. |
|
V5186 | McN3716 (Methyl palmoxirate; NSC359682) | 69207-52-9 | McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor. |
|
V4728 | MEK inhibitor | 334951-92-7 | MEK inhibitor is a MEK inhibitor (antagonist) with anti-tumor activity. |
|
V4729 | MEK-IN-1 | 870600-45-6 | MEK-IN-1 is a MEK inhibitor from patent WO2008076415A1. |
|
V4722 | MG 1 | 148274-76-4 | MG 1 (MG-1) is a novel and potent α1adrenergic receptorantagonist identified using the quantitative structure-activity relationship model. |
|
V4899 | Mibampator | 375345-95-2 | Mibampator (formerly also known as LY-451395) is a novel, potent and highly selective AMPA receptor potentiator being developed for agitation/aggression in Alzheimers disease. |
|
V4940 | MRS-2179 | 101204-49-3 | MRS-2179 (MRS2179) is a novel, potent and competitive P2Y1 receptor antagonist with anti-thrombotic/anti-platelet effects. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
